Items where authors include "Allum, W.H."

Article

Kloft, M., Budginaite, E., van Kuijk, S.M.J. et al. (7 more authors) (2025) Intra-patient comparison of microarchitecture of tumour negative lymph nodes from oesophageal cancer patients – Results from the MRC Oe02 trial. Pathology - Research and Practice, 266. 155818. ISSN 0344-0338

Grosser, B., Emmerson, J. orcid.org/0000-0002-8198-8043, Reitsam, N.G. orcid.org/0000-0002-0070-3158 et al. (7 more authors) (2024) Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial. British Journal of Cancer, 130 (3). pp. 457-466. ISSN 0007-0920

Cunningham, D., Stenning, S.P., Smyth, E.C. et al. (15 more authors) (2017) Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. The Lancet Oncology, 18 (3). pp. 357-370. ISSN 1470-2045

Conference or Workshop Item

Kloft, M., Budginaite, E., Raghuram, G. et al. (8 more authors) (2025) 457P Size of the largest nonmetastatic regional lymph node: A validated prognostic marker in patients with esophageal, junctional or gastric adenocarcinoma. In: ESMO Gastrointestinal Cancers Congress 2025, 02-05 Jul 2025, Barcelona, Spain.

Proceedings Paper

Budginaite, E., Kloft, M., Magee, D. orcid.org/0000-0003-2170-3103 et al. (9 more authors) (2025) 412P Tumour-free lymph node microarchitecture associates with tumour location-specific survival in oesophagogastric cancer: Results from the OE05 and ST03 trials. In: Annals of Oncology. ESMO Gastrointestinal Cancers Congress 2025, 02-05 Jul 2025, Barcelona, Spain. Elsevier , s161-s162.

Ntellas, P., Keogh, G.A., Gordon, A. et al. (10 more authors) (2025) 413P Mismatch repair deficiency (MMRd) in esophagogastric adenocarcinoma (ADC) following chemotherapy for resectable disease: Correlation with survival and recurrence patterns from ST03 and OE05 trials. In: Annals of Oncology. ESMO Gastrointestinal Cancers Congress 2025, 02-05 Jul 2025, Barcelona, Spain. Elsevier , s162-s162.